Start shopping and find your next favourite medicine.
Browse Catalog
PENTOXIFYLLINE 400 MG is a clinically proven hemorrheologic agent designed to restore mobility and comfort in patients with Intermittent Claudication and Peripheral Artery Disease (PAD). Unlike standard vasodilators, Pentoxifylline targets the blood’s physical properties—reducing viscosity and increasing red blood cell flexibility—to allow oxygen-rich blood to bypass narrowed arteries. This advanced therapeutic action enables patients to walk further, remain active, and reduce the painful cramping and numbness associated with restricted circulation.
Active Ingredient: Pentoxifylline 400 mg (Extended-Release)
Pharmacological Class: Xanthine Derivative / Hemorrheologic Agent
Reference Brands: Trental®, Pentoxil®, Flexital®
Main Indication: Chronic occlusive arterial disease of the limbs.
Quality Assurance: WHO-GMP certified batches with 2026/2027 expiry.
This information is for educational purposes only. Pentoxifylline is a Prescription-Only Medicine (POM). Diagnosis and treatment must be managed by a licensed healthcare provider. We strictly verify all prescriptions before dispatch to ensure patient safety and global regulatory compliance.
In 2026, clinical guidelines continue to recognize Pentoxifylline as a vital therapy for patients needing micro-circulatory support without the risks of heavy anticoagulants.
Micro-Circulation Optimization: It increases the “deformability” of red blood cells, allowing them to squeeze through oxygen-starved capillaries.
Viscosity Reduction: Lowers plasma fibrinogen levels, effectively making the blood “thinner” and easier for the heart to pump.
Vascular Protection: Reduces platelet aggregation, minimizing the risk of micro-clots in the extremities.
Sustained-Release Stability: The 400 mg ER formulation ensures a stable 12-hour therapeutic window, preventing the gastric irritation associated with standard tablets.
To ensure maximum efficacy and minimize side effects, strict adherence to pharmaceutical protocols is required.
Standard Dose: One 400 mg tablet, three times daily (TID).
Administration: Always take with food to prevent gastrointestinal upset.
Important: DO NOT CRUSH. The tablet must be swallowed whole. Breaking or chewing the tablet destroys the extended-release coating, leading to potential toxicity and immediate gastric irritation.
Clinical Timeline: Initial relief may occur in 2–4 weeks; however, full clinical benefit is reached at 8 weeks of consistent use.
| Side Effect | Frequency | Management |
| Nausea / Gas | Common | Take with a full meal. |
| Dizziness | Uncommon | Avoid driving until you know how the drug affects you. |
| Headache | Uncommon | Usually diminishes as the body adjusts to therapy. |
1.Is Pentoxifylline a blood thinner like Warfarin? No. It improves “flow” by changing cell shape and reducing viscosity, not by interfering with the primary coagulation cascade.
2.Can I use this for diabetic foot ulcers? It is frequently used as a support for diabetic micro-angiopathy, but you must consult your doctor for this specific use.
3.Why is my prescription required? We adhere to FDA, MHRA, and MOH regulations to ensure you are receiving the correct medication for your clinically diagnosed condition.
4.Does smoking affect my results? Yes. Smoking causes vasoconstriction, which directly fights against the drug’s ability to improve blood flow. Cessation is highly recommended for patient recovery.
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Very Quick delivery , good communication and easy to deal with
Great vendor .Shipment was received quickly and in great shape. Will be ordering from this company again in the future.